What is the half-life of CagriSema?

CagriSema has a half-life of ~5-7 days (both components), which is why it's typically administered Once weekly (semaglutide component; cagrilintide 2.4 mg) for optimal therapeutic effect.

How do I reconstitute CagriSema?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Growth Hormone

Phase 3

CagriSema

Also known as: Cagrilintide/Semaglutide, NNC9204-1706 + Semaglutide

Overview

Key Facts

Primary Goal: A fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) being developed by Novo Nordisk

A fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) being developed by Novo Nordisk. By targeting two complementary appetite-regulating pathways, CagriSema aims to achieve unprecedented levels of weight loss in a single weekly injection. Half-Life ~5-7 days (both components) Typical Dose 2.4–2.4 mg Frequency Once weekly (semaglutide component; cagrilintide 2.4 mg) Cycle Length Ongoing / indefinite under medical supervision

Dosing Information

Half-Life

~5-7 days (both components)

Typical Dose

2.4–2.4 mg

Frequency

Once weekly (semaglutide component; cagrilintide 2.4 mg)

Cycle Length

Ongoing / indefinite under medical supervision

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 3

Phase 2 results showed CagriSema produced approximately 15.6% weight loss at 32 weeks, significantly exceeding the individual components. The Phase 3 REDEFINE trial program is evaluating the combination across multiple obesity and diabetes populations. Early data suggest potential for >25% weight loss with extended treatment. Novo Nordisk positions CagriSema as a next-generation obesity therapy.